Abstract
Metanephric adenoma of the kidney is a rare, newly recognized entity of a unique benign renal tumor. Clinically, pain, hematuria and palpable mass are the most common presenting signs. Females predominate by well over 2:1. A higher incidence of polycythemia is often found in these patients. Only a few cases of this type of adenoma have been reported in the literature. We report on a 78–year–old female patient with a metanephric adenoma of the left kidney, which showed typical clinical, radiologic, microscopic and immunohistochemical findings. A clear cell carcinoma of the contralateral kidney was also discovered and treated.
References
1.
Gatalica Z, Grujic S, Kovatich A, Petersen RO: Metanephric adenoma: Histology, immunophenotype, cytogenetics, ultrastructure. Mod Pathol 1996;9:329–333.
2.
Eble JN: Neoplasms of the kidney: Metanephric adenoma and nephrogenic adenofibroma; in Bostwick DG, Eble JN (eds): Urologic Surgical Pathology. StLouis, Mosby, 1997, pp 118–120.
3.
Comerci SCD, Levin TL, Ruzal–Shapiro C, Berdon WE, Beckwith JB, Hibshoosh H, Hurlet–Jensen A, Sitarz AL: Benign adenomatous kidney neoplasms in children with polycythemia: Imaging findings. Radiology 1996;198: 265–268.
4.
Grignon DJ, Eble JN: Papillary and metanephric adenomas of the kidney. Semin Diagn Pathol 1998;15:41–53.
5.
Burnett AL, Epstein JI, Gearhart JB: Spectrum of differentiation in pediatric epithelial tumors of the kidney: Report of two cases. Urology 1993;42:93–98.
6.
Davis CJ Jr, Barton JH, Sesterhenn IA, Mostofi FK: Metanephric adenoma. Clinicopathological study of fifty patients. Am J Surg Pathol 1995;19:1101–1114.
7.
Brinkschmidt C, Störkel S: Das metanephroide Adenom der Niere – eine neue Differentialdiagnose zum Nephroblastom und Nierenzellkarzinom im Erwachsenenalter. Akt Urol 1996;27:214–217.
8.
Stambolis C, Alles J, Jundt G, Hatzibujas J, Gabrielides KG: öbersicht und Klassifikation der metanephrogenen Neoplasmen des Kindesalters. Pathologe 1992;3:77–84.
9.
Nonomura A, Mizukami Y: Metanephric adenoma of the kidney: An electron microscopic and immunohistochemical study with quantitative DNA measurement by image analysis. Ultrastruct Pathol 1995;19:481–488.
10.
Chefchaouni MC, Zerbib M, Homsi T, Saighi D, Flam T, Thiounn N, Debré B: L’adénome métanéphrique: une tumeur rare du rein. Journal d’Urologie 1996;102:40–43.
11.
Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DYT, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM: Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1996;1242:201– 210.
12.
Nelson JB, Oyasu R, Dalton DP: The clinical and pathological manifestations of renal tumors in von Hippel–Lindau disease. J Urol 1994;152:2221–2226.
13.
Balfe DM, McClennan BL, Stanley RJ, Weyman PJ, Sagel SS: Evaluation of renal masses considered indeterminate of Computed tomography. Radiology 1982;142:421–428.
14.
Daniel WW Jr, Hartman GW, Witten DM, Farrow GM, Kelalis PP: Calcified renal masses – A review of ten years’ experience at the Mayo Clinic. Radiology 1972;103:503–508.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
